| AbbVie (NYSE:ABBV) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $205.00 price target on the stock. This represents a 23.0% upside from the current price of $166.73. |
| Amgen (NASDAQ:AMGN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.The current price is $282.60. |
| Biogen (NASDAQ:BIIB) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.The current price is $161.00. |
| BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock. This represents a 48.0% upside from the current price of $64.21. |
| Bristol-Myers Squibb (NYSE:BMY) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.The current price is $56.77. |
| CDW (NASDAQ:CDW) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $230.00 price target on the stock. This represents a 29.3% upside from the current price of $177.93. |
| Chipotle Mexican Grill (NYSE:CMG) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $70.00 price target on the stock. This represents a 19.1% upside from the current price of $58.79. |
| Core Scientific (NASDAQ:CORZ) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $25.50 price target on the stock. This represents a 62.9% upside from the current price of $15.65. |
| Doximity (NASDAQ:DOCS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $58.00 price target on the stock. This represents a 18.8% upside from the current price of $48.84. |
| Everus (NYSE:ECG) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $71.00 price target on the stock. This represents a 25.6% upside from the current price of $56.55. |
| EMCOR Group (NYSE:EME) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $600.00 price target on the stock. This represents a 19.6% upside from the current price of $501.56. |
| First Advantage (NYSE:FA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $22.00 price target on the stock. This represents a 23.7% upside from the current price of $17.78. |
| Comfort Systems USA (NYSE:FIX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $524.00 price target on the stock. This represents a 18.8% upside from the current price of $441.00. |
| Gilead Sciences (NASDAQ:GILD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $110.00 price target on the stock. This represents a 22.9% upside from the current price of $89.48. |
| Grail (NASDAQ:GRAL) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.The current price is $14.88. |
| HealthEquity (NASDAQ:HQY) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $108.00 price target on the stock. This represents a 10.4% upside from the current price of $97.87. |
| Johnson & Johnson (NYSE:JNJ) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $190.00 price target on the stock. This represents a 24.2% upside from the current price of $152.99. |
| Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,000.00 price target on the stock. This represents a 32.9% upside from the current price of $752.68. |
| Limbach (NASDAQ:LMB) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $108.00 price target on the stock. This represents a 21.7% upside from the current price of $88.73. |
| Merck & Co., Inc. (NYSE:MRK) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.The current price is $95.00. |
| Moderna (NASDAQ:MRNA) is now covered by analysts at Wolfe Research. They set an "underperform" rating and a $40.00 price target on the stock. This represents a 7.7% upside from the current price of $37.15. |
| Mersana Therapeutics (NASDAQ:MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock. This represents a 112.8% upside from the current price of $2.35. |
| Insight Enterprises (NASDAQ:NSIT) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $220.00 price target on the stock. This represents a 46.0% upside from the current price of $150.65. |
| Pfizer (NYSE:PFE) is now covered by analysts at Wolfe Research. They set an "underperform" rating and a $25.00 price target on the stock. This represents a 0.1% upside from the current price of $24.98. |
| Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock. This represents a 50.8% upside from the current price of $762.71. |
| Starbucks (NASDAQ:SBUX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $115.00 price target on the stock. This represents a 15.0% upside from the current price of $99.97. |
| Simulations Plus (NASDAQ:SLP) is now covered by analysts at Stephens. They set an "overweight" rating and a $39.00 price target on the stock. This represents a 34.0% upside from the current price of $29.10. |
| Teladoc Health (NYSE:TDOC) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $14.00 price target on the stock. This represents a 59.1% upside from the current price of $8.80. |
| Veracyte (NASDAQ:VCYT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $50.00 price target on the stock. This represents a 40.2% upside from the current price of $35.67. |
